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Introduction: Resectoscopic surgery requires high technological skill to perform the procedure in a
limited ﬁeld of vision. With the preoperative administration of dienogest, a good surgical ﬁeld of vision
can be secured. The lesion and the normal endometrium are easily distinguished, and therefore the
removal of normal endometrium can be minimized.
Methods: Preoperative dienogest was administered to 28 patients with submucosal myomas, 18 patients
with endometrial polyps, and one patient with Asherman's syndrome. The patients began taking oral
dienogest (2 mg/d) on Day 5 of preoperative menstruation until the day before surgery. Use of dienogest
before resectoscopic surgery was approved by the Institutional Review Board of Toho Medical Center
Oomori Hospital (Tokyo, Japan; approval number 24-185).
Results: The duration of oral dienogest treatment was 14e72 days in patients with submucosal myoma
and 18e85 days in patients with endometrial polyps. Slight thickening of the endometrium occurred in
patients who were administered dienogest for 14 days. However, a thin endometrium occurred in pa-
tients who took the drug for 28 days or longer. Submucosal myomas and endometrial polyps were easily
distinguished from the normal myometrium. A sufﬁcient intrauterine surgical ﬁeld was secured to
minimize endometrial damage in all patients.
Conclusion: We found that preoperative dienogest effectively minimized endometrial damage in
resectoscopic surgery by thinning the endometrium and clearing the surgical ﬁeld of vision.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Resectoscopic surgery requires a surgeon to perform the pro-
cedure in a limited ﬁeld of vision. A thin endometrium is preferred
because a thick endometrium decreases the surgical ﬁeld of vision.1
Surgeries used to be scheduled immediately after menstruation,
when the endometrium is thin. However, scheduling a surgery
immediately after menstruation is usually difﬁcult because the
timing of patient admission and the availability of the operation
room need to coincide. In some patients, the endometrium is thick
or it is difﬁcult to secure a good surgical ﬁeld of vision because theonﬂicts of interest to report.
rics and Gynecology, Toho
hi, Ota-ku, Tokyo, 143-8541,
suchiya).
for Gynecologic Endoscopy and Minimpatients are still menstruating, even after the surgery. By using
preoperative dienogest, surgery scheduling is not affected by the
patient's menstrual cycle, a good surgical ﬁeld of vision is secured,
the lesion and the normal endometrium are easily distinguished,
and the removal of normal endometrium can be minimized. We
report the effectiveness of preoperative dienogest, which inhibits
endometrial proliferation, in patients with submucosal myomas or
endometrial polyps who are scheduled for resectoscopic surgery.
Materials and methods
This study included patients clinically diagnosed as having
endometriosis, based on dysmenorrhea or hypermenorrhea, or
patients who had documented endometriosis and were scheduled
for laparoscopic surgery and subsequently diagnosed as having
submucosal myoma or endometrial polyp (based on transvaginal
sonography or MRI) and wished to undergo resectoscopic surgery.
Preoperative dienogest was administered to 28 patients withally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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patient with Asherman's syndrome. They were scheduled for sur-
gery and able to receive inpatient treatment. They gave informed
consent in advance. Oral administration of dienogest (2 mg/d) was
started on Day 5 of preoperative menstruation until the day before
surgery. Two laminaria (size S) were inserted the night before
surgery as a preoperative treatment. A monopolar or bipolar
resectoscope (Karl Storz Endoskope; Karl Storz Endoskope, Tut-
tlingen, Germany) was used for the resectoscopic surgery in pa-
tients under general anesthesia. As the perfusate, D-sorbitol was
used with the monopolar resectoscope and isotonic sodium chlo-
ride solution was used with the bipolar resectoscope. Use of
dienogest before resectoscopic surgery was approved by the Insti-
tutional Review Board of the Toho Medical Center Oomori Hospital
(Tokyo, Japan; approval number 24-185).
Results
The duration of oral administration dienogest treatment was
14e72 days in patients with submucosal myomas, 18e85 days in
patients with endometrial polyps, and 12 days in patients with
Asherman's syndrome. Resectoscopic myomectomy lasted 8e102
minutes, resectoscopic polypectomy lasted 6e27 minutes, and
resectoscopic adhesiotomy lasted for 12 minutes. The amount of
perfusate used was 2000e18,000 mL in resectoscopic myomec-
tomy, 1200e4500 mL in resectoscopic polypectomy, and 3000 mL
in resectoscopic adhesiotomy. A slight thickening of the endome-
trium only occurred with the administration of dienogest for 14
days. However, patients who had taken the medication for at least
28 days had a thin endometrium. Submucosal myomas or endo-
metrial polyps were clearly distinguished from the normal myo-
metrium. In all patients, a sufﬁcient intrauterine surgical ﬁeld was
secured to minimize endometrial damage. No endometrium was
found in patients treated with dienogest for approximately 56 days.
Their intrauterine ﬁndings were comparable to those of patients
treated preoperatively with a gonadotropin-releasing hormone
agonist (GnRHa; Figures 1e4). No menopause-like symptoms were
induced by dienogest before surgery. Nearly all patients had
irregular vaginal bleeding associated with dienogest, although the
blood was removed with the perfusate during resectoscopic sur-
gery to prevent the obscuring of the surgical ﬁeld. No patient had
any serious complications such as water intoxication.
Discussion
In 1978, the ﬁrst resectoscopic surgery was reported by Neu-
wirth2 who used a resectoscope for transurethral resection to
remove a myoma. In 1986, Lin and colleagues3 named the proce-
dure “transcervical resection.” With the development of speciﬁcFigure 1. Dienogest admisurgical devices, transcervical resection is indicated for the treat-
ment of various disorders such as submucosal myomas, endome-
trial polyps, deformity of the uterus, and intrauterine adhesions.
Patients undergoing resectoscopic surgery at our hospital increased
from eight patients in 2004 to 34 patients in 2012. Patients un-
dergoing resectoscopic myomectomy have also increased signiﬁ-
cantly from two patients in 2005 to 25 patients in 2012. Our
hospital surgical guidelines for submucosal myoma recommend
performing laparoscopic myomectomy for myomas >3 cm in
diameter and resectoscopic myomectomy for myomas <3 cm in
diameter with a protrusion of >60%. In some patients with a sub-
mucosal myoma of <3 cm and little protrusion, excessive shrinkage
of a submucosal myoma associated with GnRHa made it difﬁcult to
identify the lesion during surgery. Preoperative GnRHa adversely
affected the surgical procedure in these patients. Therefore, as
much as possible, we avoid using GnRHa for small submucosal
myomas with little protrusion.
It is difﬁcult to schedule a resectoscopic surgery based on the
estimated cycle immediately after the last menstruation without
preoperative medication because the expected onset of menstru-
ation, the timing of the patient's admission, and the availability of
the operation room at the hospital need to coincide. In some pa-
tients, menstruation did not start as expected after admission.
Some patients have a thick endometrium in the luteal phase; in
other patients, menstrual blood obscures the surgical ﬁeld. The
border between the myometrium and a submucosal myoma or
endometrial polyp is difﬁcult to identify in resectoscopic surgery of
the uterus in patients with a thick endometrium. The surgery may
damage the endometrium or cause serious complications such as
uterine perforation. By thinning the endometrium, the lesion and
the myometrium can be clearly distinguished and endometrial
removal can be minimized. The future fertility of the patient may
therefore be protected. Use of oral contraceptives before resecto-
scopic surgery to minimize the endometrial thickness has been
previously reported.4e6 However, use of oral contraceptives within
4 weeks of surgery is contraindicated in Japan. A GnRHa or
dienogest containing no estrogen may be the only choice to adjust
the surgical schedule. Dienogest is a fourth-generation progestin
developed by Regine Sitruk-Ware in 2004.7 Norethisterone is a
ﬁrst-generation progestin and has progesterone and androgenic
actions. Compared to the ﬁrst-generation progestin, the second-
generation progestin levonorgestrel and the third-generation pro-
gestin desogestrel have an enhanced progesterone action on
inhibiting ovulation. However, adverse reactions such as acne,
hirsutism, and weight increase are more frequent because the
androgen action is simultaneously enhanced. The fourth-
generation progestin dienogest has no androgen action and has a
5.3-times higher progesterone action, compared to the ﬁrst-
generation progestin.8nistered for 21 days.
Figure 2. Dienogest administered for 14 days. The locus of the arrows indicates the thickened endometrium.
Figure 3. Dienogest administered for 18 days.
Figure 4. Dienogest administered for 56 days.
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endometrial cells. Okada et al9 report in their in vitro study of
cultured endometrial stromal cells that dienogest signiﬁcantly in-
hibits cell proliferation at a concentration of >107 mol/L. Fu et al10
report similar results in their study of cultured endometrial stromal
cells derived from ovarian endometriosis. Irahara et al11 repoted in
a clinical study, dienogest was administered to nine patients to
evaluate the change in hormone levels, endometrial thickness, and
follicular diameter from baseline to 16 weeks, based on trans-
vaginal ultrasound and the endometrium thinned from 11.4 mm at
baseline to 5.2 mm at 2 weeks after the administration of dienogest
and never thickened againdit remained at 3.8e5.6 mm, which
suggested that dienogest inhibits endometrial proliferation. Saito
et al12 report the usefulness of dienogest administered 7e21 days
before resectoscopic surgery.
There is no established timing or duration of preoperative
dienogest treatment in patients undergoing resectoscopic surgeryand laparoscopy for endometriosis. In some of our patients who
had undergone concurrent laparoscopy and resectoscopic surgery
or had been diagnosed with endometriosis and scheduled for
resectoscopic surgery, preoperative dienogest caused endometrial
thinning, resulting in identiﬁcation of endometrial lesion based on
transvaginal ultrasound for the ﬁrst time and underwent surgery
thereafter. Therefore, our patients were treated for a longer time,
compared to patients treated by Saito et al.12 Endometrial thinning
started ~14 days after starting dienogest, although the endome-
trium did not disappear with short-term treatment. It is more
difﬁcult to secure a surgical ﬁeld of vision in resectoscopic myo-
mectomy, which requires a higher level of surgical technique in
comparison to resectoscopic polypectomy; therefore, patients with
submucosal myomas may need to receive dienogest longer than
patients with endometrial polyps. However, the treatment duration
could be shorter than the duration in the previous case. After
receiving dienogest, nearly all patients had irregular vaginal
T. Tsuchiya et al. / Gynecology and Minimally Invasive Therapy 5 (2016) 16e19 19bleeding before undergoing resectoscopy. According to Momoeda
and colleagues,13 irregular vaginal bleeding is most frequent after
5e8 weeks of dienogest treatment. Patients should therefore be
thoroughly informed of the likelihood of irregular vaginal bleeding
associatedwith dienogest. Irregular vaginal bleeding did not hinder
the surgical procedure because the blood was rinsed away by the
perfusate in the intrauterine cavity to clear the surgical ﬁeld.
A submucosal myoma reduces by administering GnRHa, but
may cause excessive bleeding. In addition, in the submucosal my-
oma low projecting rate make us stop to use GnRHa, without
reduction of the protruding rate due to reduction of myoma by
administering the dienogest, effective way of endometrium to
thinning considered. We found that preoperative dienogest effec-
tively minimized endometrial damage in resectoscopic surgery by
thinning the endometrium and clearing the surgical ﬁeld of vision.
We will further evaluate the timing and duration of treatment to
establish preoperative dienogest therapy for resectoscopic surgery.References
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